Published in Int J Pharm on April 22, 2008
Delivery of chlorambucil using an acoustically-triggered perfluoropentane emulsion. Ultrasound Med Biol (2010) 1.34
Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech (2010) 0.93
Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech (2014) 0.92
Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res (2014) 0.81
Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats. Contrast Media Mol Imaging (2013) 0.78
A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo. AAPS PharmSciTech (2012) 0.76
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm Res (2015) 0.76
Characterization and in vivo evaluation of novel lipid-chlorambucil nanospheres prepared using a mixture of emulsifiers for parenteral administration. Int J Nanomedicine (2010) 0.75
Disrupting tumour blood vessels. Nat Rev Cancer (2005) 4.35
Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today (2002) 2.32
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther (2011) 1.86
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake. J Inorg Biochem (2007) 1.84
MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther (2010) 1.77
Drug transfer and metabolism by the human placenta. Clin Pharmacokinet (2004) 1.76
Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol (2002) 1.63
Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm (2003) 1.61
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J (2011) 1.57
Interactions of herbs with cytochrome P450. Drug Metab Rev (2003) 1.44
Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res (2003) 1.43
Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release (2002) 1.40
Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol (2011) 1.35
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33
Superimposed acute hepatitis E infection in patients with chronic liver disease. Indian J Gastroenterol (2004) 1.31
Quality, safety and efficacy in the 'off-label' use of medicines. Curr Drug Saf (2007) 1.28
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res (2006) 1.27
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer (2010) 1.24
Electrochemically controlled drug delivery based on intrinsically conducting polymers. J Control Release (2010) 1.22
Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos (2007) 1.22
Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. J Math Biol (2004) 1.22
A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One (2009) 1.21
Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur J Pharm Biopharm (2004) 1.21
Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS (2008) 1.16
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet (2013) 1.13
A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis (2008) 1.13
UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol (2002) 1.13
Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. Int J Pharm (2003) 1.12
A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. J Math Biol (2003) 1.11
Endoscopic management of postoperative bile leaks. Hepatobiliary Pancreat Dis Int (2006) 1.10
Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem (2003) 1.10
Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum Reprod (2002) 1.09
ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol (2005) 1.08
The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J (2007) 1.07
Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res (2006) 1.05
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm (2008) 1.03
Improving the oral bioavailability of beneficial polyphenols through designed synergies. Genes Nutr (2009) 1.00
Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res (2006) 0.98
Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs (2011) 0.98
Epigenetic regulation in human melanoma: past and future. Epigenetics (2015) 0.98
PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Res (2011) 0.97
Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev (2009) 0.97
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer (2005) 0.95
Permeability issues in nasal drug delivery. Drug Discov Today (2002) 0.95
A validated high performance liquid chromatographic method for analysis of nicotine in pure form and from formulations. J Pharm Biomed Anal (2003) 0.94
Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J Pharm Biomed Anal (2004) 0.94
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer (2012) 0.93
Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices. J Control Release (2005) 0.93
Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet (2013) 0.93
A distal regulatory region is required for constitutive and IFN-beta-induced expression of murine TLR9 gene. J Immunol (2005) 0.93
Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J Pharmacol Exp Ther (2004) 0.92
Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Front Oncol (2013) 0.91
Centrosomal dysregulation in human metastatic melanoma cell lines. Cancer Genet (2011) 0.91
Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem Pharmacol (2004) 0.90
Crystal modifications and dissolution rate of piroxicam. Acta Pharm (2011) 0.90
The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90
Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing. J Pharm Biomed Anal (2005) 0.90
Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol (2010) 0.89
Spectrum of atypical celiac disease in North Indian children. Indian Pediatr (2004) 0.89
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Oncol Res (2005) 0.88
Evaluation of policies to support drug development in New Zealand. Health Policy (2010) 0.88
Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol (2006) 0.88
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One (2011) 0.88
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110alpha inhibitors. Bioorg Med Chem (2007) 0.87
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs (2010) 0.87
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemother Pharmacol (2006) 0.87
Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol (2014) 0.87
Modelling the flow [corrected] cytometric data obtained from unperturbed human tumour cell lines: parameter fitting and comparison. Bull Math Biol (2004) 0.86
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells. Invest New Drugs (2011) 0.86
Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment. Drug Dev Ind Pharm (2002) 0.86
Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev (2002) 0.86
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clin Cancer Res (2008) 0.86
Transport of thalidomide by the human intestinal caco-2 monolayers. Eur J Drug Metab Pharmacokinet (2005) 0.85
Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci (2005) 0.85
An overview on chemical derivatization and stability aspects of selected avermectin derivatives. Chem Pharm Bull (Tokyo) (2012) 0.84
Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. Int J Pharm (2008) 0.84
MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma. Front Oncol (2013) 0.84
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Invest New Drugs (2007) 0.84
Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem (2012) 0.84
3'-azido-3'-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol Appl Pharmacol (2003) 0.83
Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res (2012) 0.83
Osmotic pumps in drug delivery. Crit Rev Ther Drug Carrier Syst (2004) 0.83
High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol (2006) 0.83
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. Oncol Res (2002) 0.83
Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett (2009) 0.83
NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res (2007) 0.82
Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res (2004) 0.82
Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. J Theor Biol (2009) 0.82
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorg Med Chem (2005) 0.82
Evaluation of mucoadhesive coatings of chitosan and thiolated chitosan for the colonic delivery of microencapsulated probiotic bacteria. J Microencapsul (2012) 0.81
Electrically switchable polypyrrole film for the tunable release of progesterone. Ther Deliv (2013) 0.81
Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact (2004) 0.81
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
Synthesis and cytotoxic activity of N-[(alkylamino)alkyl]carboxamide derivatives of 7-oxo-7H-benz[de]anthracene, 7-oxo-7H-naphtho[1,2,3-de]quinoline, and 7-oxo-7H-benzo[e]perimidine. Bioorg Med Chem (2005) 0.80